Anticancer drug irinotecan inhibits homomeric 5-HT 3A and heteromeric 5-HT 3AB receptor responses

Biochemical and Biophysical Research Communications

Volumn 415, Issue 2, 2011, Pages 416-420

  Nakamura, Yukiko ^a   Ishida, Yusuke ^a   Yamada, Takahiro ^a   Shimada, Shoichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT; 5 HT 3 receptor; Anti cancer; Anti emetic; Ion channel; Vagus nerve

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; SMALL INTESTINE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; HUMANS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; XENOPUS LAEVIS;

EID: 84855896511     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.084     Document Type: Article

References (35)

1. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987, 47:5944-5947.
2. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991, 51:4187-4191.
3. Kaneda N., Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 1990, 50:1721-1725.
4. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 1997, 8:837-855.
5. Reardon D.A., Desjardins A., Peters K.B., Vredenburgh J.J., Gururangan S., Sampson J.H., McLendon R.E., Herndon J.E., Coan A., Threatt S., Friedman A.H., Friedman H.S. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011, 10.1002/cncr.26188.
6. Rowinsky E.K., Grochow L.B., Ettinger D.S., Sartorius S.E., Lubejko B.G., Chen T.L., Rock M.K., Donehower R.C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 1994, 54:427-436.
7. Minami M., Endo T., Hamaue N., Hirafuji M. Serotonin and anticancer drug-induced emesis. Yakugaku Zasshi 2004, 124:491-507.
8. Filip M., Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol. Rep. 2009, 61:761-777.
9. 2+. J. Biol. Chem. 2003, 278:712-717.
10. Niesler B., Frank B., Kapeller J., Rappold G.A. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003, 310:101-111.
11. Davies P.A., Pistis M., Hanna M.C., Peters J.A., Lambert J.J., Hales T.G., Kirkness E.F. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999, 397:359-363.
12. Sanchez L.A., Holdsworth M., Bartel S.B. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Pharmacoeconomics 2000, 18:533-556.
13. Maricq A.V., Peterson A.S., Brake A.J., Myers R.M., Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991, 254:432-437.
14. Krieg P.A., Melton D.A. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 1984, 12:7057-7070.
15. Das P., Bell-Horner C.L., Machu T.K., Dillon G.H. The GABA(A) receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors. Neuropharmacology 2003, 44:431-438.
16. Stevens R., Rusch D., Solt K., Raines D.E., Davies P.A. Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J. Pharmacol. Exp. Ther. 2005, 314:338-345.
17. Hayrapetyan V., Jenschke M., Dillon G.H., Machu T.K. Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res. Mol. Brain Res. 2005, 142:146-150.
18. Masuda N., Kudoh S., Fukuoka M. Irinotecan (CPT-11): pharmacology and clinical applications. Crit. Rev. Oncol. Hematol. 1996, 24:3-26.
19. Fuchs C., Mitchell E.P., Hoff P.M. Irinotecan in the treatment of colorectal cancer. Cancer Treat. Rev. 2006, 32:491-503.
20. Choi S.H., Tsuchida Y., Yang H.W. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Lett. 1998, 124:15-21.
21. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 1993, 84:697-702.
22. Abigerges D., Chabot G.G., Armand J.P., Herait P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 1995, 13:210-221.
23. de Forni M., Bugat R., Chabot G.G., Culine S., Extra J.M., Gouyette A., Madelaine I., Marty M.E., Mathieu-Boue A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 1994, 54:4347-4354.
24. Canal P., Gay C., Dezeuze A., Douillard J.Y., Bugat R., Brunet R., Adenis A., Herait P., Lokiec F., Mathieu-Boue A. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1996, 14:2688-2695.
25. Hamberg P., De Jong F.A., Brandsma D., Verweij J., Sleijfer S. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol. 2008, 47:974-978.
26. Blum I., Nessiel L., Graff E., Harsat A., Gabbay U., Sulkes J., Raz O., Vered Y. Food preferences, body weight, and platelet-poor plasma serotonin and catecholamines. Am. J. Clin. Nutr. 1993, 57:486-489.
27. Ortiz J., Artigas F., Gelpi E. Serotonergic status in human blood. Life Sci. 1988, 43:983-990.
28. Cubeddu L.X., Hoffmann I.S., Fuenmayor N.T., Malave J.J. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br. J. Cancer 1992, 66:198-203.
29. Cubeddu L.X., O'Connor D.T., Parmer R.J. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J. Clin. Oncol. 1995, 13:681-687.
30. Johnson D.S., Heinemann S.F. Detection of 5-HT3R-A, a 5-HT3 receptor subunit, in submucosal and myenteric ganglia of rat small intestine using in situ hybridization. Neurosci. Lett. 1995, 184:67-70.
31. Morales M., Wang S.D. Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J. Neurosci. 2002, 22:6732-6741.
32. van der Bol J.M., Loos W.J., de Jong F.A., van Meerten E., Konings I.R., Lam M.H., de Bruijn P., Wiemer E.A., Verweij J., Mathijssen R.H. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. Eur. J. Cancer 2010, 47:831-838.
33. Gebauer A., Merger M., Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch. Pharmacol. 1993, 347:137-140.
34. Minami M., Tamakai H., Ogawa T., Endo T., Hamaue N., Hirafuji M., Yoshioka M., Blower P.R. Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine. Res. Commun. Mol. Pathol. Pharmacol. 1995, 89:131-142.
35. Tremblay P.B., Kaiser R., Sezer O., Rosler N., Schelenz C., Possinger K., Roots I., Brockmoller J. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. 2003, 21:2147-2155.